Shorter neoadjuvant therapy (≤8 weeks) boosts surgical success in pancreatic cancer.

• Surgical resection rate significantly higher with ≤8 weeks (66.7%) versus >8 weeks (33.5%).
• This trend holds for both resectable (73.9% vs 44.7%) and borderline resectable cases (66.4% vs 22.5%).

Longer therapy does not improve resection margins or survival, suggesting risks in delaying surgery.

• No significant differences in R0 resection, response rates, or 1- to 5-year survival rates between the two duration groups.